科学图书馆
-
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registrySahlén A, Varenhorst C, Lagerqvist B et al. -
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS RegistryJoyce LC, Baber U, Mehran R et al.
-
One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trialNatsuaki M, Morimoto T, Kimura T et al.
-
Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age?W Sumaya, RF Storey.
-
Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCIHY Wang, RL Gao, KF Dou et al.
-
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trialJ Silvain, B Lattuca, ALPHEUS investigators et al.
-
Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)Leonardi S, Franzone A, Piccolo R et al.
-
A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trialWJ Jang, JB Lee, YB Song et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
